Animals
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cell Line
Cell Line, Tumor
Cisplatin
/ administration & dosage
Cohort Studies
DNA Repair
/ genetics
Female
Humans
Mice, Inbred NOD
Mice, Knockout
Mice, SCID
Muscles
/ pathology
Mutation, Missense
Neoplasm Invasiveness
Survival Analysis
Urinary Bladder Neoplasms
/ drug therapy
Xenograft Model Antitumor Assays
Xeroderma Pigmentosum Group D Protein
/ genetics
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
02
04
2018
revised:
04
06
2018
accepted:
02
07
2018
pubmed:
8
7
2018
medline:
14
4
2020
entrez:
8
7
2018
Statut:
ppublish
Résumé
DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients. Here, we sought to define the role of the nucleotide excision repair (NER) gene Somatic missense mutations in We used our functional assay to test the NER capacity of clinically observed Our data support a direct role for
Identifiants
pubmed: 29980530
pii: 1078-0432.CCR-18-1001
doi: 10.1158/1078-0432.CCR-18-1001
pmc: PMC6434536
mid: NIHMS1016538
doi:
Substances chimiques
Xeroderma Pigmentosum Group D Protein
EC 3.6.4.12
ERCC2 protein, human
EC 5.99.-
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
977-988Subventions
Organisme : NCI NIH HHS
ID : K08 CA219504
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA218976
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA182587
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA082088
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2018 American Association for Cancer Research.
Références
Eur Urol. 2018 May;73(5):751-759
pubmed: 29248319
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):E633-42
pubmed: 23382212
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Nat Med. 2014 Jun;20(6):682-8
pubmed: 24836576
Cancer. 2009 Sep 15;115(18):4104-9
pubmed: 19517476
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Hum Mutat. 2014 Feb;35(2):151-64
pubmed: 24323938
Clin Cancer Res. 2017 Jul 15;23(14):3610-3618
pubmed: 28137924
PLoS One. 2014 Jan 28;9(1):e85896
pubmed: 24489677
J Exp Med. 2009 Dec 21;206(13):3031-46
pubmed: 19934020
Eur Urol. 2017 Jun;71(6):952-960
pubmed: 28081860
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016
Nat Rev Mol Cell Biol. 2014 Jul;15(7):465-81
pubmed: 24954209
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Neoplasia. 2003 May-Jun;5(3):245-54
pubmed: 12869307
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
J Clin Oncol. 2014 Dec 1;32(34):3801-9
pubmed: 25366678
Cell. 2013 Mar 28;153(1):17-37
pubmed: 23540688
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Carcinogenesis. 2000 Apr;21(4):551-5
pubmed: 10753184
Cancer Discov. 2014 Oct;4(10):1140-53
pubmed: 25096233
Cancer Res. 1995 Aug 1;55(15):3438-43
pubmed: 7542171
Urol Oncol. 2011 May-Jun;29(3):252-8
pubmed: 19450992
J Clin Oncol. 2018 Jun 10;36(17):1685-1694
pubmed: 29489427
JAMA Oncol. 2016 Aug 1;2(8):1094-6
pubmed: 27310333
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Eur Urol. 2014 Jul;66(1):120-37
pubmed: 24613684
Lancet. 1999 Aug 14;354(9178):533-40
pubmed: 10470696